Summary
- Current Price
- As of today, NBIX price is $152.25, up +1.78% on
- Current Price All-Time High
- NBIX price is currently -4.95% below its historical high of $160.18 set on
- Market Cap
- NBIX current market cap is $15B, up +31.63% over the past 365 days
- PE Ratio
- NBIX current PE ratio is 23.41
- Revenue
- NBIX current annual revenue is $2.86B, up +21.45% year-over-year
- Next Earnings
- The next earnings release for NBIX is on
Profile
| Metric | Value |
|---|---|
| Full Name | Neurocrine Biosciences, Inc. |
| Ticker | NASDAQ: NBIX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Specialty & Generic Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | neurocrine.com |
| Employees | 1,800 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $152.25 | |
| Price, 1D Change | +1.78% | |
| Market Cap | $15B | |
| - | ||
| PE Ratio | 23.41 | |
| Beta | 0.84 | |
| Revenue | $3B | |
| Revenue, 1Y Change | +21.45% | |
| EPS | $4.67 | |
| EPS, 1Y Change | +41.87% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $4.67 | |
| EPS Estimate | N/A | $9.06 |
| EPS Est. Change | N/A | +94.03% |
| Revenue | $2.86B | |
| Revenue Estimate | N/A | $3.71B |
| Revenue Est. Change | N/A | +29.54% |
| Current Price | $152.25 | |
| Price Target | - | $186.00 |
| Price Tgt. Change | - | +22.17% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $6.58 | $3.29 | -49.95% | |
| $6.81 | $4.67 | -31.48% | |
| $9.06 | N/A | +94.03% | |
| $10.89 | N/A | +133.28% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.36B | $2.36B | -0.04% | |
| $2.84B | $2.86B | +0.58% | |
| $3.71B | N/A | +29.54% | |
| $4.27B | N/A | +49.32% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +29.55% | |
| Price, 3Y | +55.52% | |
| Market Cap, 1Y | +31.63% | |
| Market Cap, 3Y | +60.26% | |
| Revenue, 1Y | +21.45% | |
| Revenue, 3Y | +92.15% | |
| EPS, 1Y | +41.87% | |
| EPS, 3Y | +198.89% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Date | Value |
|---|---|---|
| Current Price | $152.25 | |
| SMA 200 | $137.60 | |
| SMA 200 vs Price | -9.62% | |
| SMA 50 | $131.62 | |
| SMA 50 vs Price | -13.55% | |
| Beta | 0.84 | |
| ATR | $4.43 | |
| 14-Day RSI | 78.42 | |
| 10-Day Volatility | 41.60% | |
| 1-Year Volatility | 30.36% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $2.86B | |
| EPS | $4.67 | |
| Gross Profit | $2.81B | |
| Gross Margin | 98.18% | |
| Operating Profit | $636.50M | |
| Operating Margin | 22.25% | |
| Net Income | $478.60M | |
| Net Margin | 16.73% | |
| EBITDA | $666.60M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.14 | |
| 3.39 | ||
| 3.30 | ||
| - | ||
| 6 | ||
| 7.75 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 23.41 | |
| 4.93 | ||
| 4.49 | ||
| - | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $3.25B | |
| $1.48B | ||
| $4.75B | ||
| $2.52B | ||
| $1.50B | ||
| $743.40M | ||
| Total Debt | $471.30M | |
| $56.00M | ||
| $104.90M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $2.38B | ||
| $2.17B | ||
| $52.10M | ||
| $0.00 | ||
| $30.10M | ||
| $0.00 | ||
| $226.80M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $782.70M | ||
| -$264.40M | ||
| -$38.30M | ||
| Capex | $34.00M | |
| $748.70M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| JP Morgan | → | |
| Truist Securities | → | |
| Wedbush | → | |
| RBC Capital | → | |
| Piper Sandler | → | |
| Morgan Stanley | → | |
| Guggenheim | → | |
| Citigroup | → | |
| Leerink Partners | → | |
| Morgan Stanley | → |
Analyst sentiment
Institutional ownership
Screeners with NBIX
FAQ
What is the ticker symbol for Neurocrine Biosciences, Inc.?
The ticker symbol for Neurocrine Biosciences, Inc. is NASDAQ:NBIX
Does Neurocrine Biosciences, Inc. pay dividends?
No, Neurocrine Biosciences, Inc. does not pay dividends
What sector is Neurocrine Biosciences, Inc. in?
Neurocrine Biosciences, Inc. is in the Healthcare sector
What industry is Neurocrine Biosciences, Inc. in?
Neurocrine Biosciences, Inc. is in the Specialty & Generic Drug Manufacturers industry
What country is Neurocrine Biosciences, Inc. based in?
Neurocrine Biosciences, Inc. is headquartered in United States
When did Neurocrine Biosciences, Inc. go public?
Neurocrine Biosciences, Inc. initial public offering (IPO) was on May 23, 1996
Is Neurocrine Biosciences, Inc. in the S&P 500?
No, Neurocrine Biosciences, Inc. is not included in the S&P 500 index
Is Neurocrine Biosciences, Inc. in the NASDAQ 100?
No, Neurocrine Biosciences, Inc. is not included in the NASDAQ 100 index
Is Neurocrine Biosciences, Inc. in the Dow Jones?
No, Neurocrine Biosciences, Inc. is not included in the Dow Jones index
When was Neurocrine Biosciences, Inc. last earnings report?
Neurocrine Biosciences, Inc.'s most recent earnings report was on May 5, 2026
When does Neurocrine Biosciences, Inc. report earnings?
The next expected earnings date for Neurocrine Biosciences, Inc. is July 29, 2026
Data Sources & References
- NBIX Official Website www.neurocrine.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/914475/000091447526000007/0000914475-26-000007-index.htm
- NBIX Profile on Yahoo Finance finance.yahoo.com/quote/NBIX
- NBIX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/nbix